RecruitingNCT06449885

A Cohort Study in Newly Diagnosed MZL

A Prospective, Multi-center, Cohort Study in Newly Diagnosed Marginal Zone B-cell Lymphoma

Sponsor

Fudan University

Enrollment

2,500 participants

Start Date

May 30, 2024

Study Type

OBSERVATIONAL

Conditions

Marginal Zone Lymphoma

Summary

Describe the clinical features, diagnosis and treatment status, disease course and primary outcomes of different subtypes of marginal zone B-cell lymphoma (MZL), observe the therapeutic efficacy and safety of different treatment modalities.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This observational cohort study follows newly diagnosed patients with marginal zone lymphoma (MZL) — a slow-growing type of blood cancer — to learn more about disease patterns, treatment outcomes, and biological markers over time. **You may be eligible if...** - You are 18 or older - You have been newly diagnosed with marginal zone lymphoma within the past 6 months and have not yet started anti-tumor therapy - You are willing to provide blood samples and tumor tissue - You are willing to be followed long-term **You may NOT be eligible if...** - You have HIV infection - You are unable to come to the hospital for regular follow-up visits - You have already started treatment for lymphoma Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERpatients receive optimal treatment or follow-up according to the characteristics of the disease

Patients with MZL who are eligible for enrollment will be evaluated by the investigator and the enrolled patients will receive long-term follow-up after collecting medical history information, biological samples, and oncology data according to the study protocol. This study does not specify a detailed treatment modality, and patients receive optimal treatment or follow-up according to the characteristics of the disease.

Locations(1)

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06449885

Related Trials

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

NCT05006716127 locations

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

NCT05100862277 locations

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

NCT0529473129 locations

Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma

NCT044913701 location

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

NCT065335799 locations